Biosimulation Expansion And AI Products Will Drive Long Term Margin Upside

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

13 Dec 25

Updated

02 Jul 26

Views

Not Invested

Shared on 02 Jul 26

Fair value Decreased 38%

CERT: Peer Deal Premium Will Highlight Depressed Multiple Over Coming Years

A peer in the same niche gets bought out at a big premium, and some analysts argue it shows the market may be undervaluing Certara despite recent target cuts. Meanwhile, leadership changes and a heavier investment push put the spotlight on whether the company can turn its pipeline into steadier growth.

4 views

Fair Value vs Share Price

US$10

vs US$7.9120.9% undervalued

2.5%

Revenue growth

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Certara

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet with moderate growth potential.

Market capUS$1.2b

PB1.2x

Estimated Growth2.3%

Dividend YieldN/A

Full analysis

CEO & management

Jon Resnick

CEO

1.8yrs

CEO Tenure

Provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.